



上海源叶生物科技有限公司  
 Shanghai yuanye Bio-Technology Co., Ltd  
 电话: 021-61312973 传真: 021-55068248  
 网址: www.shyuanye.com  
 邮箱: shyysw@sina.com

产品名称: **Tonabersat**  
 产品别名: **SB-220453; 托那博沙**

生物活性:																										
<b>Description</b>	Tonabersat is a gap-junction modulator.																									
<b>IC<sub>50</sub> &amp; Target</b>	Gap-junction <sup>[1]</sup>																									
<b>In Vitro</b>	Tonabersat, a novel benzopyran derivative, inhibits cortical spreading depression (CSD) and therefore might be able to inhibit the early migraine mechanisms <sup>[1]</sup> .																									
<b>In Vivo</b>	Treatment with either Tonabersat (10 mg/kg) or Meclofenamate (20 mg/kg) as single agents significantly inhibit progression of metastatic lesions. Addition of carboplatin to either agent profoundly inhibits brain metastasis <sup>[2]</sup> .																									
<b>Solvent&amp;Solubility</b>	<p><b>In Vitro:</b></p> <p>DMSO : ≥ 100 mg/mL (255.22 mM)</p> <p>H<sub>2</sub>O : &lt; 0.1 mg/mL (insoluble)</p> <p>* "≥" means soluble, but saturation unknown.</p>																									
		<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing</td> <td>1 mM</td> <td>2.5522 mL</td> <td>12.7610 mL</td> <td>25.5219 mL</td> </tr> <tr> <td>5 mM</td> <td>0.5104 mL</td> <td>2.5522 mL</td> <td>5.1044 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2552 mL</td> <td>1.2761 mL</td> <td>2.5522 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing	1 mM	2.5522 mL	12.7610 mL	25.5219 mL	5 mM	0.5104 mL	2.5522 mL	5.1044 mL	10 mM	0.2552 mL	1.2761 mL	2.5522 mL			
	Solvent	Mass			Concentration																					
			1 mg	5 mg	10 mg																					
	Preparing	1 mM	2.5522 mL	12.7610 mL	25.5219 mL																					
5 mM		0.5104 mL	2.5522 mL	5.1044 mL																						
10 mM		0.2552 mL	1.2761 mL	2.5522 mL																						
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液: 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p>																										
<p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存: 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶</p>																										
<p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.5 mg/mL (6.38 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (6.38 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀, 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p>																										
<p>2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline)</p> <p>Solubility: 2.5 mg/mL (6.38 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 2.5 mg/mL (6.38 mM)的均匀悬浊液, 悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中, 混合均匀。</p>																										



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>3.请依序添加每种溶剂: 10% DMSO →90% corn oil</p> <p>Solubility: ≥ 2.5 mg/mL (6.38 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (6.38 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。</p>
<b>References</b>	<p>[1]. Silberstein SD, et al. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia. 2009 Nov;29 Suppl 2:17-27.</p> <p>[2]. Chen Q, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016 May 18;533(7604):493-8.</p> <p>[3]. Kim Y, et al. Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels. Neurotherapeutics. 2017 May 30.</p>
<b>实验参考:</b>	
<b>Animal Administration</b>	<p>Mice<sup>[2]</sup></p> <p>Athymic NCR nu/nu mice, Cr:NIH bg-nu-xid mice, B6129SF1/J, C57BL/6J-<i>Tmem173gt/J</i> 'golden ticket', and C57/Bl/6J mice are used at 5-6 weeks of age. For inducible knockdown experiments, mice are given doxycycline hyclate in the drinking water (2 mg/mL) and the diet 14 days after injection of cancer cells. For drug treatment experiments, mice are intraperitoneally injected with Carboplatin (5 mg/kg per 5 days), Tonabersat (MedChem Express) (10 mg/kg per day), or meclofenamic acid sodium salt (20 mg/kg per day). Vehicle (10% DMSO in polyethylene glycol 400) is used in control mice. Quantification of tumour burden is by Bio-luminescent imaging (BLI), performed using an IVIS Spectrum Xenogen instrument and analysed using Living Image software v.2.50.</p>
<b>References</b>	<p>[1]. Silberstein SD, et al. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia. 2009 Nov;29 Suppl 2:17-27.</p> <p>[2]. Chen Q, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016 May 18;533(7604):493-8.</p> <p>[3]. Kim Y, et al. Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels. Neurotherapeutics. 2017 May 30.</p>